15.01.2020 • News

Milliken Agrees to Acquire Borchers

Milliken Agrees to Acquire Borchers (c) Borcher
Milliken Agrees to Acquire Borchers (c) Borcher

Plastics additives and colorants manufacturer Milliken has agreed to acquire Borchers Group, a global specialty chemicals company specializing in high-performance coating additives and specialty catalyst solutions.

Seller is The Jordan Company (TJC). All three companies are US-based, Milliken at Spartanburg, South Carolina, Borchers at Westlake, Ohio and TJC in New York. The acquisition is expected to close during the course of this month, subject to customary closing conditions. Financial terms have not been disclosed.

Borchers produces additives for the coatings, inks and adhesives markets and has a comprehensive range of cobalt-free driers, dispersants, rheology modifiers, wetting agents, polymerization catalysts and adhesion promoters.

Russ Rudolph, senior vice president of Milliken's chemical division, said the addition of the Ohio company’s expertise in specialty coating additives expands his company’s reach and further builds its comprehensive solutions portfolio as it pursues its strategic objective to develop a global range of growth platforms.

Devlin Riley, president and CEO of Borchers, added that the combination, in particular the  and depth of Milliken's technology, will help it build out its own global brand.

 

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read